Mavali-Zadeh A, Gatto E, Lettieri R, Bokharaie B, Caravella A, D'Ottavi C, et al.. Biomass-derived Lignin Nanoparticles for the Sustained Delivery of Vascular Endothelial Growth Factor-C. Molecular Pharmaceutics [Internet]. Submitted;. https://doi.org/10.1101/2025.04.23.649697

López-Cerdá S, Molinaro G, ParejaTello R, Correia A, Künig S, Steinberger P, et al.. Study of the Synergistic Immunomodulatory and Antifibrotic Effects of Dual-Loaded Budesonide and Serpine1 siRNA Lipid?Polymer Nanoparticles Targeting Macrophage Dysregulation in Tendinopathy. ACS Applied Materials & Interfaces [Internet]. 2024;16(15):18643 - 18657. https://pubs.acs.org/doi/10.1021/acsami.4c02363

Mukenge S, Jha SK, Catena M, Manara E, Leppänen V?M, Lenti E, et al.. Investigation on the role of biallelic variants in VEGF?C found in a patient affected by Milroy?like lymphedema. Molecular Genetics & Genomic Medicine [Internet]. 2020;00:e1389. https://onlinelibrary.wiley.com/doi/abs/10.1002/mgg3.1389

Fang S, Chen S, Nurmi H, Leppänen V-M, Jeltsch M, Scadden DT, et al.. VEGF-C Protects the Integrity of Bone Marrow Perivascular Niche. Blood [Internet]. 2020;:accepted - for publication. https://ashpublications.org/blood/article/doi/10.1182/blood.2020005699/463465/VEGF-C-Protects-the-Integrity-of-Bone-Marrow

Jha SK, Rauniyar K, Chronowska E, Mattonet K, Maina EW, Koistinen H, et al.. KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D. eLife [Internet]. 2019;8:e44478. https://elifesciences.org/articles/44478

Mattonet K, Wilting J, Jeltsch M. The genetic causes of primary lymphedema. In: Weissleder H, Schuchhardt C. Erkrankungen des Lymphgefäßsystems. 6th ed. Cologne: Viavital Verlag; 2015. pp. 210-229. 

Mattonet K, Jeltsch M. Heterogeneity of the origin of the lymphatic system. [German]. Lymphologie in Forschung und Praxis [Internet]. 2015;19(2):84-88. http://www.dglymph.de/fileadmin/global/pdfs/LymphForsch_2-15.pdf

Batchu KChaithanya, Hokynar K, Jeltsch M, Mattonet K, Somerharju P. Substrate efflux propensity is the key determinant of iPLA-?-mediated glycerophospholipid hydrolysised. Journal of Biological Chemistry [Internet]. 2015;. http://www.jbc.org/content/early/2015/02/23/jbc.M115.642835.abstract

Leppänen V-M, Tvorogov D, Kisko K, Prota AE, Jeltsch M, Anisimov A, et al.. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Proceedings of the National Academy of Sciences of the United States of America [Internet]. 2013;110(32):12960 - 12965. http://www.pnas.org/content/110/32/12960.long

Villefranc JA, Nicoli S, Bentley K, Jeltsch M, Zarkada G, Moore JC, et al.. A truncation allele in vascular endothelial growth factor c reveals distinct modes of signaling during lymphatic and vascular development. Development. 2013;140(7):1497-506. 

Saharinen P, Helotera H, Miettinen J, Norrmen C, D'Amico G, Jeltsch M, et al.. Claudin-like protein 24 interacts with the VEGFR-2 and VEGFR-3 pathways and regulates lymphatic vessel development. Genes Dev [Internet]. 2010;24(9):875 - 80. http://view.ncbi.nlm.nih.gov/pubmed/20439428

Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974

Karpanen T, Bry M, Ollila HM, Seppänen-Laakso T, Liimatta E, Leskinen H, et al.. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy. Circ Res [Internet]. 2008;103(9):1018 - 26. http://view.ncbi.nlm.nih.gov/pubmed/18757827

Li X, Tjwa M, Van Hove I, Enholm B, Neven E, Paavonen K, et al.. Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol [Internet]. 2008;28(9):1614 - 20. http://view.ncbi.nlm.nih.gov/pubmed/18511699

Tammela T, He Y, Lyytikkä J, Jeltsch M, Markkanen J, Pajusola K, et al.. Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. Circ Res [Internet]. 2007;100(10):1468 - 75. http://view.ncbi.nlm.nih.gov/pubmed/17478733

Keskitalo S, Tammela T, Lyytikka J, Karpanen T, Jeltsch M, Markkanen J, et al.. Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein. Circ Res [Internet]. 2007;100(10):1460 - 7. http://view.ncbi.nlm.nih.gov/pubmed/17478734

Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al.. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734

Veikkola T, Lohela M, Ikenberg K, Mäkinen T, Korff T, Saaristo A, et al.. Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J [Internet]. 2003;17(14):2006 - 13. http://view.ncbi.nlm.nih.gov/pubmed/14597670

Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, et al.. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol [Internet]. 2003;161(6):1163 - 77. http://view.ncbi.nlm.nih.gov/pubmed/12810700

Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, et al.. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J [Internet]. 2001;20(6):1223 - 31. http://view.ncbi.nlm.nih.gov/pubmed/11250889

Jussila L, Veikkola T, Jeltsch M, Thurston G, McDonald D, Achen M, et al.. Signalling via VEGFR-3 is sufficient for lymphangiogenesis in transgenic mice. In Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Miami Beach, Florida; 2001. 

Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al.. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J [Internet]. 2001;20(4):672 - 82. http://view.ncbi.nlm.nih.gov/pubmed/11179212

Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, et al.. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000;102(18):2262 - 8. http://view.ncbi.nlm.nih.gov/pubmed/11056103

Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, et al.. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A [Internet]. 1998;95(20):11709 - 14. http://view.ncbi.nlm.nih.gov/pubmed/9751730

Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, et al.. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A [Internet]. 1998;95(2):548 - 53. http://view.ncbi.nlm.nih.gov/pubmed/9435229

Pepper MS, Mandriota SJ, Jeltsch M, Kumar V, Alitalo K. Vascular endothelial growth factor (VEGF)-C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity. J Cell Physiol [Internet]. 1998;177(3):439 - 52. http://view.ncbi.nlm.nih.gov/pubmed/9808152

Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, et al.. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (80- ) [Internet]. 1997;276(5317):1423 - 5. http://view.ncbi.nlm.nih.gov/pubmed/9162011

Oh SJ, Jeltsch MM, Birkenhäger R, McCarthy JE, Weich HA, Christ B, et al.. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol [Internet]. 1997;188(1):96 - 109. http://view.ncbi.nlm.nih.gov/pubmed/9245515